Proteonomix, a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, has formed a new subsidiary, THOR BioPharma, based in Nevada, according to Fierce Biotech.

THOR BioPharma has been established to gain Proteonomix entry into the bio-pharmaceutical market. Proteonomix plans to utilize THOR BioPharma as a platform for technology it will seek to license that focuses on pharmaceutical products.

THOR Biopharma's mission is to develop therapeutic biological agents capable of enhancing stem cell therapies to provide clinical treatment of patients with debilitating diseases. THOR will focus initially on the licensing and development of therapeutic agents for critically ill patients.